Compare Logitech International SA (LOGI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Tango Therapeutics Inc. — how do they compare? Logitech International SA trades at $101.24 (market cap $14.62B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Logitech International SA is far larger — about 3.9× Tango Therapeutics Inc.'s market cap, and Logitech International SA pays a 1.61% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Tango Therapeutics Inc. for 0 Days on average.
| LOGI | TNGX | |
|---|---|---|
Market Cap | $14.62B | $3.75B |
Volume | 811,529 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $126.69 | $32.90 |
52-Week Low | $85.84 | $7.50 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $12.95B | $2.77B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.16, up 2.88% today, with a bullish technical signal from moving averages and support at $101. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.85 beating expectations of $1.26. Fundamentals show robust profitability with a net margin of 16.28% and ROE of 35.29%, while recent news highlights new product launches and partnerships.
The outlook is positive with a consensus price target of $107, offering ~6% upside. Key opportunities include product innovation and market share gains, but risks involve chip shortages and competitive pressures. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid execution challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
